[1] 中华医学会肝病学分会、消化病学分会、内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 实用肝脏病杂志,2016,19(5):Ⅰ-ⅩⅤⅠ. [2] Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93–110. [3] Assis DN. Chronic complications of cholestasis: evaluation and management. Clin Liver Dis, 2018, 22(3): 533–544. [4] Thomas WW, Stephen AR, Alexander S, et al. Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates. Eur J gastroentero hepatol, 2020,[ahead of print]. [5] Takeshita E, Kumagi T, Matsui H, et al. Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis. J Gastroenterol, 2003, 38(11): 1060–1065. [6] 祁小龙. 肝硬化门静脉高压无创时代我们如何把握. 中华肝脏病杂志, 2018, 26(4):241-244. [7] Moctezuma-Velazquez C, Saffioti F, Tasayco-Huaman S, et al. Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol, 2019, 114(3): 446–452. [8] Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with pbc and psc. Hepatology, 2006, 43(5): 1118–1124. [9] 陈刚, 许建明, 张飞娟, 等. 原发性胆汁性肝硬化112例发生食管胃静脉曲张危险因素的临床研究. 中华消化杂志, 2015, 35(8):526-529. [10] Patanwala I, Mcmeekin P, Walters R, et al. A validated clinical tool for the prediction of varices in pbc: the new castle varices in PBC score. J Hepatol, 2013, 59(2): 327–335. [11] 陶明玲, 张世斌, 吴燕京, 等. 原发性胆汁性肝硬化患者食管静脉曲张特点及其无创预测指标研究. 实用肝脏病杂志, 2017, 20(4): 439-442. [12] Colli A, Gana JC, Yap J, et al. Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis. Cochrane Database Syst Rev, 2017, 4: CD008759. [13] 汪兴禄, 徐琴, 朱翠焕, 等. 原发性胆汁性肝硬化食管静脉曲张患者相关指标的临床价值. 中华传染病杂志, 2017, 35(4): 203-207. [14] Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology, 2013, 144(1): 102–111.e1. [15] Giannini E G, Savarino V. Noninvasive assessment of varices needing treatment in patients with advanced chronic liver disease: no one should be left behind. Hepatology, 2017, 65(6): 2131–2131. [16] Wang H, Wen B, Chang X, et al. Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis. J Hepatol, 2021, 74(3):584-592. [17] Antonio C, Federico R, Giovanni M, et al. A combined model based on spleen stiffness measurement and baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. J Hepatol, 2018, 69(2): 308-317. [18] Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol, 2017, 67(2): 399–411. [19] Li Q, Wang R, Guo X, et al. Contrast-enhanced ct may be a diagnostic alternative for gastroesophageal varices in cirrhosis with and without previous endoscopic variceal therapy. Gastroenterol Res Pract, 2019: 6704673. [20] Liu F, Ning Z, Liu Y, et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (chess1701): a prospective multicenter study. EBio Med, 2018, 36: 151–158. |